Source:http://linkedlifedata.com/resource/pubmed/id/14684297
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2003-12-19
|
| pubmed:abstractText |
A novel series of DHODH inhibitors was developed based on a lead which was obtained by a docking procedure and a medicinal chemistry exploration. The activity of the initial lead was improved by a QSAR method to yield low nanomolar inhibitors.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0960-894X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
5
|
| pubmed:volume |
14
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
55-8
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading | |
| pubmed:year |
2004
|
| pubmed:articleTitle |
Discovery of a novel series of DHODH inhibitors by a docking procedure and QSAR refinement.
|
| pubmed:affiliation |
4SC AG, Am Klopferspitz 19a, 82152 Martinsried, Germany. leban@4sc.com
|
| pubmed:publicationType |
Journal Article
|